Tofacitinib experience in patients with enteropathic arthritis
Immunotherapy, cilt.15, sa.8, ss.619-626, 2023 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 15 Sayı: 8
- Basım Tarihi: 2023
- Doi Numarası: 10.2217/imt-2022-0110
- Dergi Adı: Immunotherapy
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE
- Sayfa Sayıları: ss.619-626
- Anahtar Kelimeler: Crohn disease, enteropathic arthritis, inflammatory bowel disease, spondyloarthropathy, tofacitinib, ulcerative colitis
- Ankara Yıldırım Beyazıt Üniversitesi Adresli: Evet
Özet
Background/aim: The JAK-STAT pathway is involved in the pathogenesis of both the inflammatory bowel disease (IBD) and spondyloarthropathy group of diseases. The purpose of this study was to evaluate the effectiveness of tofacitinib, a Janus kinase inhibitor, in the treatment of enteropathic arthritis (EA). Materials & methods: The study included seven patients, four from the authors' follow-up and three from the literature. All cases were recorded for demographic characteristics, comorbidities, IBD and EA symptoms, medical treatments and changes in clinical and laboratory results with treatment. Results & conclusion: Clinical and laboratory remission in terms of IBD and EA was achieved in three patients after tofacitinib treatment. For both spondyloarthritis spectrum diseases and IBD, tofacitinib may be an appropriate choice, as its efficacy has been shown in both conditions.